NOT FOR DISTRIBUTION
Header cover image

Market Cap

CA$101.1m

Last Updated

2021/05/08 06:53 UTC

Data Sources

Company Financials

Executive Summary

SQI Diagnostics Inc., a precision medicine company, discovers, develops, produces, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. More Details


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has SQI Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SQD is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: SQD's weekly volatility (12%) has been stable over the past year.


Market Performance


7 Day Return

-4.8%

SQD

2.3%

CA Medical Equipment

1.9%

CA Market


1 Year Return

78.8%

SQD

32.1%

CA Medical Equipment

36.9%

CA Market

Return vs Industry: SQD exceeded the Canadian Medical Equipment industry which returned 32.1% over the past year.

Return vs Market: SQD exceeded the Canadian Market which returned 36.9% over the past year.


Shareholder returns

SQDIndustryMarket
7 Day-4.8%2.3%1.9%
30 Day-19.2%-6.9%2.2%
90 Day-38.5%-19.3%8.3%
1 Year78.8%78.8%32.1%32.1%41.4%36.9%
3 Year37.2%37.2%-64.1%-64.1%30.1%17.7%
5 Year-26.3%-26.3%86.7%86.7%60.1%36.2%

Long-Term Price Volatility Vs. Market

How volatile is SQI Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SQI Diagnostics undervalued compared to its fair value and its price relative to the market?

32.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SQD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SQD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SQD is unprofitable, so we can't compare its PE Ratio to the XN Medical Equipment industry average.

PE vs Market: SQD is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SQD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SQD is overvalued based on its PB Ratio (32.8x) compared to the CA Medical Equipment industry average (7.5x).


Future Growth

How is SQI Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

60.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SQI Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has SQI Diagnostics performed over the past 5 years?

-12.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SQD is currently unprofitable.

Growing Profit Margin: SQD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SQD is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.

Accelerating Growth: Unable to compare SQD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SQD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.2%).


Return on Equity

High ROE: SQD has a negative Return on Equity (-347.25%), as it is currently unprofitable.


Financial Health

How is SQI Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: SQD's short term assets (CA$5.8M) exceed its short term liabilities (CA$2.3M).

Long Term Liabilities: SQD's short term assets (CA$5.8M) exceed its long term liabilities (CA$4.8M).


Debt to Equity History and Analysis

Debt Level: SQD's debt to equity ratio (73.1%) is considered high.

Reducing Debt: SQD's debt to equity ratio has increased from 62% to 73.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SQD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SQD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.4% each year


Dividend

What is SQI Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SQD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SQD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SQD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SQD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SQD's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Rob Chioini (55 yo)

0.75

Tenure

CA$62,477

Compensation

Mr. Robert L. Chioini, also known as Rob, founded Rockwell Medical, Inc. (also known as, Rockwell Medical Technologies Inc) and served as its Chief Executive Officer from February 1997 to May 22, 2018. He ...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD51.45K) is below average for companies of similar size in the Canadian market ($USD156.82K).

Compensation vs Earnings: Insufficient data to compare Rob's compensation with company performance.


Leadership Team

Experienced Management: SQD's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: SQD's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SQD insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.


Top Shareholders

Company Information

SQI Diagnostics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SQI Diagnostics Inc.
  • Ticker: SQD
  • Exchange: TSXV
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$101.094m
  • Shares outstanding: 342.69m
  • Website: https://www.sqidiagnostics.com

Number of Employees


Location

  • SQI Diagnostics Inc.
  • 36 Meteor Drive
  • Toronto
  • Ontario
  • M9W 1A4
  • Canada

Listings


Biography

SQI Diagnostics Inc., a precision medicine company, discovers, develops, produces, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The comp...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/08 06:53
End of Day Share Price2021/05/07 00:00
Earnings2020/12/31
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.